Thursday, April 21, 2011

Theralase Expands US Sales Force and Appoints Director of Investor Relations

Company adds experienced staff to build the revenue stream and improve shareholder value
April 21, 2011 (Marketwire Canada) --
TORONTO, ONTARIO -- Theralase Technologies Inc. (TSX VENTURE:TLT) announced today that effective immediately, Mr. Brad Green, Ms. Kim Hillman, Mr. Derek McDonald and Mr. Cliff Majni have been appointed as Territory Sales Managers - Therapeutic Division, reporting to Scott Bleue, National Sales Manager. As well, Mr. Greg Bewsh has been appointed as Director of Investor Relations reporting to Roger Dumoulin-White, President and CEO.
Brad Green will be representing Theralase in the Southeast United States. He has over 20 years of experience in the medical device industry with 14 years as a sales professional which includes 5 years in a managerial role. He has sold to hospitals, physician offices, veterinary facilities and acute care centers.
Kim Hillman will be representing Theralase in the Western United States.  She has 2 years direct experience in therapeutic laser sales and over 8 years in the pharmaceutical industry. Throughout this time, Kim has developed key relationships with thought leaders in the medical community across the Western United States.
Derek McDonald will be representing Theralase in Ontario. He has over 23 years experience in sales, with 13 years in medical laser sales.
Cliff Majni will be representing Theralase in the Midwest United States. He has over 15 years of sales experience in the pharmaceutical and medical equipment industries.
Greg Bewsh will be the new Director of Investor Relations for Theralase. He has more than 20 years experience in investor relations and financial services. He has advised clients with respect to strategic investor relations, corporate disclosure, governance, regulatory issues, raising capital, social media, and liquidity enhancement. Previously, Greg acquired extensive experience as Director of Investor Relations and Corporate Communications at two TSX and NASDAQ listed companies.
Roger Dumoulin-White, President & CEO of Theralase Technologies Inc., stated  “I am excited by the quality of the new hires to our team, coming to us with significant experience in their respective fields. The improving US economy and the public’s desire for high efficacy, drug-free treatments in an aging population, is creating a significant opportunity for Theralase in 2011 and beyond. These new additions will support this vision.”
Visit the corporate or regulatory website at or for more information.
About Theralase Technologies Inc.
Theralase Technologies Inc. designs, develops and manufactures patented, super-pulsed laser technology utilized in bio-stimulation and bio-destruction applications in the United States, Canada and internationally. The technology is safe and effective in the treatment of chronic pain, neural muscular-skeletal conditions and wound care. When combined with patented light-sensitive Photo Dynamic Compounds, Theralase laser technology is able to specifically target and destroy cancers, bacteria and viruses.
This press release contains forward-looking statements which reflect the Company's current expectations regarding future events. The forward-looking statements involve risks and uncertainties. Actual results could differ materially from those projected herein. The Company disclaims any obligation to update these forward-looking statements.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchanges) accepts responsibility for the adequacy or accuracy of this release.
Theralase Technologies Inc.
Roger Dumoulin - White,                                                                        Greg Bewsh
President & CEO                                                                                   Director of Investor Relations
416-447-8455 ext. 225                                                                            416-447-8455 ext. 262                                                                    

No comments:

Post a Comment